ADAMAS PHARMACEUTICALS, INC. Inactive Instrument
Adamas Pharmaceuticals, Inc.
Equities
ADMS
US00548A1060
Biotechnology & Medical Research
Presenter SpeechRaghuram Selvaraju (Analysts)Hello, and welcome to our audience and to another...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company's portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson's disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer's type.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +50.47% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| -1.62% | 11.98B |
